There is one clinical trial.
This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in five patient cohorts for up to 150 previously treated patients with any systemic therapy (Cohort 1: 30 Patients that have HER2-positive or HER2-negative breast cancer with HER2 activating mutations, Cohort 2: 30 Patients that have colorectal cancer with HER2 activating mutations, Cohort 3: Patients that have solid tumors (except NSCLC, breast cancer, or colorectal cancer) with HER2 activating mutations, Cohort 4: 30 Patients that have high-grade glioma with EGFR activating mutations, and Cohort 5: 30 Patients that have solid tumors (except NSCLC or high-grade glioma) with EGFR activating mutations.
I655V, V659E, R678Q, V697L Kinase Domain. --- I655V ---
Description: Proportion of patients whose best overall response is confirmed CR or PR
Measure: Objective Response Rate (ORR) Time: 24 monthsDescription: Time from the first CR or PR until progressive disease or death
Measure: Duration of Response (DoR) Time: 24 monthsDescription: Proportion of patients whose best overall response is CR, PR, or SD
Measure: Disease Control Rate (DCR) Time: 24 months